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In two independent Cell Stem Cell reports, the Morrisey and Mori groups show that human and mouse
somatic cells can be reprogrammed to produce induced pluripotent stem cells by expressing microRNAs,
completely eliminating the need for ectopic protein expression (Anokye-Danso et al., 2011; Miyoshi et al.,
2011).Reprogramming of somatic cells into
induced pluripotent stem cells (iPSCs)
can be achieved by a small set of protein
factors, generally transcription factors,
whose expression is either very specific
to or much higher in embryonic stem cells
(ESCs) than in differentiated cells. Several
groups have used microRNAs (miRNAs)
to promote the transcription factor-medi-
ated reprogramming process, and now
two independent groups have derived
human and mouse iPSCs by adding
miRNAs, in the absence of any additional
protein factors (Anokye-Danso et al.,
2011; Miyoshi et al., 2011) (Table 1).
miRNAs are small noncoding RNAs that
can modulate messenger RNA (mRNA)
expression by base pairing between
a few nucleotides in the miRNA (the
seed sequence) and complementary
sequences within the open reading frame
or the 30 untranslated region of the target
mRNA, leading to destabilization of the
mRNA or inhibition of protein synthesis.
They are synthesized from longer precur-
sors into mature 22-mers by the action
of the microprocessor and Dicer enzy-
matic machineries. Multiple miRNAs are
often found in clusters in the genome
and expressed in a cell type-specific
manner, similar to transcription factors.
Importantly, each miRNA can target and
suppress hundreds of messenger RNAs
(mRNAs); hence expression of a single
miRNA could dramatically change the
expression profile and identity of a cell.
Since reprogramming to pluripotency
requires precisely such a dramatic
change in transcriptional profile, Morrisey
and colleagues followed up on this idea
and demonstrated in a recent issue ofCell Stem Cell that mouse and human
iPSCs can be generated with high effi-
ciency from fibroblasts, by expressing
five miRNAs that are normally highly ex-
pressed in ESCs (Anokye-Danso et al.,
2011). The study in this issue by Mori
and colleagues further advances the
notion that overexpression of miRNAs is
sufficient for reprogramming by deriving
bonafide mouse and human iPSCs by
simply transfecting a small set of mature
miRNA (Miyoshi et al., 2011; Table 1).
As part of an effort to develop reprog-
ramming methods that either allow re-
programming factor expression without
the need for genomic integration of
foreign DNA or that replace their function
with other molecules, the Morrisey study
convincingly demonstrates that lentiviral
expression of themir-302–mir-367 cluster
in fibroblasts induces iPSCs (Anokye-
Danso et al., 2011). While it is astonishing
that a few ESC-specific miRNAs are suffi-
cient for iPSC generation, it is also
remarkable that iPSCs are obtained with
very high frequency. Even though difficult
to directly compare, miRNA-based re-
programming appears to be two orders
of magnitude more efficient than tran-
scription factor-mediated reprogram-
ming, when using similar viral titers. Fully
reprogrammed colonies appeared within
6–8 days with mouse embryonic fibro-
blasts and 15 days with human fibro-
blasts, indicating that the process is also
relatively fast. miRNA derived-iPSCs
(mi-iPSCs) are similar to ESCs in standard
tests for pluripotency, including contribu-
tion to adult chimeras formousemi-iPSCs
and differentiation into the three germ
layers in the context of teratomas forCell Stem Chuman mi-iPSCS. Efficient silencing of
the miRNA-expressing lentiviral cassette
in the reprogrammed cells confirms
a stable change in cell fate.
The relatively high efficiency of miRNA-
based reprogramming should make it
possible to generate mi-iPSCs by simply
transfecting mature, double-stranded
miRNAs. A similar idea has allowed the
generation of transcription factor-derived
iPSCs by transfection of mRNAs coding
for the reprogramming transcription
factors, but requires a technically chal-
lenging protocol, which may make clinical
applications difficult (Warren et al., 2010).
Remarkably, the Mori group has now suc-
ceeded in reprogramming human and
mouse adipose stromal cells, which are
multipotent, by repeatedly transfecting
a cocktail of seven miRNAs belonging to
themir-302, mir-200, andmir-369 families
(Miyoshi et al., 2011). However, compared
to the viral delivery of miRNA precursors
(Anokye-Danso et al., 2011), the efficiency
is considerably lower and decreases
further when fibroblasts are targeted as
the starting cell type. Given that the Mori
group transfected mature miRNAs only
four times within the first 8 days of reprog-
ramming, the efficiency of this strategy
might improve with repeated transfection
over the course of reprogramming.
Furthermore, it is possible that the need
for each of the miRNA families may differ
during the course of reprogramming and
that sequential delivery paradigms,
dictated by when a particular miRNA is
most effective, could be developed.
Since, different miRNAs are used in both
studies, one could test various combina-
tions of these in reprogramming.ell 8, June 3, 2011 ª2011 Elsevier Inc. 599
Table 1. Summary of iPSC Reprogramming Experiments with miRNAs
Starting Cell
Transcription
Factors Used
miRNAs
Employed
miRNA
Delivery Remarks
miRNA Targets
Tested References
Mouse
embryonic
fibroblasts
inducible OSMKa
secondary
system
mmu-mir-200b or
mmu-mir-200c
single transfection
of miRNA mimics
enhancement of
reprogramming,
promotion of MET
Samavarchi-
Tehrani et al., 2010
Mouse
embryonic
fibroblasts
retroviral
OSK or OSMK
mmu-mir-106b or
mmu-mir-93 or
mmu-mir-106a or
mmu-mir-17
repeated
transfection of
miRNA mimics
enhancement of
faithful
reprogramming,
acceleration of MET
p21, Tgf-bR2 Li et al., 2011
Mouse
embryonic
fibroblasts
retroviral
OSK or OSMK
mmu-mir-106a/
18b/20b/19b/
92a/363
retroviral
expression of
entire cluster
enhancement of
faithful
reprogramming,
mir-106a and -20b
have strongest
effect
Liao et al., 2011
Mouse
embryonic
fibroblasts
retroviral
OSK or OSMK
mmu-mir-302b/
302c/302a/302d/
367
retroviral
expression of
entire cluster
strong
enhancement of
faithful
reprogramming,
mir-367 not
required for this
effect, promotion
of MET
Tgf-bR2 Liao et al., 2011
Mouse
embryonic
fibroblasts
retroviral
OSK or OSKM
mmu-mir-291-3p
or mmu-mir-294
or mmu-mir-295
or mmu-mir-302d
repeated
transfection of
miRNA mimics
enhancement of
faithful
reprogramming,
but only with OSK
Judson et al., 2009
Mouse
embryonic
fibroblasts
none mmu-mir-302b/
302c/302a/302d/
367
lentiviral
expression
of entire cluster
faithful
reprogramming
with high
frequency, HDAC2
inhibition required
Anokye-Danso
et al., 2011
Mouse
adipose
stromal cells
none mmu-mir-200c +
mmu-mir-
302a,b,c,d + mmu-
mir-369-3p,-5p
repeated
transfection of
miRNA mimics
faithful
reprogramming
Miyoshi et al., 2011
Human
fibroblasts
retroviral
OSK or OSMK
hsa-mir-302b or
hsa-mir-372 or
mmu-mir-294
repeated
transfection of
miRNA mimics
enhancement of
faithful
reprogramming,
acceleration of MET
p21, RBL2,
MeCP2, TGF-bR2,
RHOC and others
Subramanyam
et al., 2011
Human skin
cancer cells
none hsa-mir-302a/b/c/d retroviral
expression of
polycistronic
cassette
some evidence of
faithful
reprogramming,
but incomplete
characterization
Lin et al., 2008
Human hair
follicle cells
none hsa-mir-302a/b/c/d electroporation
of polycistronic
cassette
some evidence of
faithful
reprogramming,
but incomplete
characterization
Lin et al., 2011
Human
fibroblasts
none mmu-mir-302b/
302c/302a/302d/
367
lentivral
expression
of entire cluster
faithful
reprogramming
with high
frequency
Anokye-Danso
et al., 2011
Human adipose
stromal cells
(and dermal
fibroblasts)
none hsa-mir-200c +
hsa-mir-
302a,b,c,d + hsa-
mir-369-3p,-5p
repeated
transfection of
miRNA mimics
faithful
reprogramming
Miyoshi et al., 2011
aO, Oct4; S, Sox2; M, cMyc; K, Klf4.
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miRNAs guide the transition to pluripo-
tency through the same steps as Oct4,
Sox2, Klf4, and cMyc. Interestingly, pluri-
potency gene activation coincides with
the appearance ofmi-iPSC colonies (Ano-
kye-Danso et al., 2011), suggesting that,
as in transcription factor-mediated re-
programming, the activation of the core
pluripotency network is the last step,
perhaps reflecting the generality of the
process. Given that miRNAs can act
through hundreds of targets, and that
both the Morrissey and Mori protocols
utilize miRNA families with different seed
sequences and thereby different mRNA
targets, it may be challenging to unravel
the detailed mechanisms by which
miRNAs induce pluripotency. In support
of this notion, the Morrisey study demon-
strates that, when expressed without mir-
367, the mir-302 family can induce the
expression of the pluripotency markers
Nanog, Sox2, and Zfp42, but not of Oct4
(Anokye-Danso et al., 2011). It remains
unclear whether mir-367 expression on
its own can activate the Oct4 locus. Inter-
estingly, the mir-302s have previously
been suggested to be sufficient for
reprogramming to the iPSC state,
although iPSC isolation had not been
well described and efficiency was not re-
ported (Lin et al., 2008, 2011). These
earlier studies required ectopic miRNA
expression above the ESC level,
suggesting that the specific response to
miRNAs could also depend on their
cellular concentration. Intriguingly, a
similar notionmay be true for transcription
factor-induced reprogramming, where
Oct4 levels appear to affect the reprog-
ramming outcome.
Clues to the function of miRNAs in re-
programming also come from studies
which have used some of the above
miRNAs to enhance reprogramming
induced by Oct4, Sox2, cMyc, and Klf4
(Table 1). A recurring target of these
reprogramming-enhancing miRNAs is
the TGF-b signaling pathway (Li et al.,
2011; Liao et al., 2011; Samavarchi-
Tehrani et al., 2010; Subramanyam et al.,
2011). Inhibition of this pathway acceler-
ates the mesenchymal-to-epithelial tran-
sition that occurs when fibroblastsreprogram. Other targets include chro-
matin regulators, such as MeCP2 and
the histone demethylases Aof2 and Aof1,
although the latter have been confirmed
only by luciferase reporter assays (Lin
et al., 2011; Subramanyam et al., 2011).
Furthermore, reprogramming of mouse
fibroblasts with the mir-302–367 cluster
is completely dependent on the presence
of the histone deacetylase (HDAC) inhib-
itor valproic acid (VPA) (Anokye-Danso
et al., 2011). HDAC2 is a known target
of VPA, and the authors demonstrate
that fibroblasts lacking HDAC2 can be
reprogrammed by mir-302–367 with high
efficiency, independently of VPA. It may
be that reprogramming of human fibro-
blasts does not depend on VPA because
these cells already exhibit low levels of
HDAC2. Generally, it appears that reprog-
ramming-enhancing miRNAs counteract
pathways that limit reprogramming, as
the cell-cycle inhibitor p21, which
functions as a barrier to transcription
factor-induced reprogramming, is also
suppressed by some of these miRNAs
(Li et al., 2011; Subramanyam et al.,
2011) (Table 1). Together, these observa-
tions suggest that transitioning to an ESC-
like cell cycle, while inhibiting TGF-
b signaling and allowing chromatin
changes, are all key to reprogramming.
However, suppression of each putative
target only partially recapitulates the
improvement in reprogramming due to
miRNAs. Thus, this picture is likely incom-
plete, and many targets of these miRNAs
in reprogramming remain unknown. In
addition, the mRNA targets may vary
during the reprogramming process, with
changing cell identity. It is also surprising
that miRNAs, which suppress mRNAs,
can mediate reprogramming, given that
transcription factor-mediated reprogram-
ming, in contrast, functions to activate
many genes, particularly those involved
in pluripotency. Interestingly, mir-369-3,
used in the Mori study, is one of the very
few miRNAs reported to activate protein
translation upon cell-cycle arrest (Vasu-
devan et al., 2007).
The application of reprogramming
methods to regenerative therapy will
require transient and nonintegrative
means of delivering the effectors, suchCell Stem Cas the synthetic, mature miRNAs
described here. However, given the
ongoing debate regarding the extent of
molecular and functional similarities
between transcription factor-derived
iPSCs and ESCs and the potential for
genomic instability during the reprogram-
ming process, mi-iPSCs will require close
scrutiny prior to therapeutic use.
Finally, several groups have directly
converted one adult cell type to another,
without traversing the pluripotent state.
The Morrisey and Mori studies suggest
that it should also be possible to enhance
or mediate these lineage conversion
events with miRNAs. Screening cell
type-specific miRNAs for transdifferentia-
tion activities, rather than focusing on
transcription factors, may be a useful
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